MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SLNO stock logo

SLNO

Soleno Therapeutics, Inc.

$39.49
2.5
 (6.76%)
Exchange:  NASDAQ
Market Cap:  2.121B
Shares Outstanding:  18681
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Anish Bhatnagar
Full Time Employees:  115
Address: 
203 Redwood Shores Parkway
Redwood City
CA
94065
US
Website:  https://soleno.life
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/07 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue00190,405
Gross Profit00187,705
EBITDA-37,030-173,63228,383
Operating Income-41,384-187,67114,950
Net Income-38,988-175,85020,890

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets180,691330,972563,830
Total Liabilities23,18485,859113,715
Total Stockholders Equity157,507245,113450,115
Total Debt40352,8262,690
Cash and Cash Equivalents169,68187,92870,106

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-24,940-69,09646,798
Capital Expenditure0-218-73
Free Cash Flow-24,940-69,31446,725
Net Income-38,988-175,85020,890
Net Change in Cash155,079-81,753-17,822

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,378,595.105Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,736,480.177Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,552,534.200Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)1,143,976.543Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)1,440,954.333Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)1,288,313.516Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)610,306.879Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)824,377.516Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)714,349.352Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,294,206.156Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,630,183.748Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,457,497.791Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)13.150Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)15.170Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)11.230Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
11.14
?Net Income
 (TTM)
: 
-175850000  ?P/E
 (TTM)
: 
100.52
?Enterprise Value
 (TTM)
: 
2.054B  ?EV/FCF
 (TTM)
: 
43.78
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.06  ?ROIC
 (TTM)
: 
0.02
?Net Debt
 (TTM)
: 
-238611000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
4.67  ?Current Ratio
 (TTM)
: 
5.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
10.00Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SLNO Intrinsic Value

Common questions about SLNO valuation

Is SLNO (SLNO) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for SLNO (SLNO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SLNO a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SLNO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SLNO’s P/E ratio?

You can see SLNO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SLNO?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SLNO a good long-term investment?

Whether SLNO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

SLNO

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

6.76
MARKETSnap

Trading Metrics:

Open:    Previous Close: 
Day Low:    Day High: 
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

SLNO EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – RGRD Law
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit
SLNO ALERT: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read